2022
Functional status at 30 and 90 days after mild ischaemic stroke
Gardener H, Romano L, Smith E, Campo-Bustillo I, Khan Y, Tai S, Riley N, Sacco R, Khatri P, Alger H, Mac Grory B, Gulati D, Sangha N, Olds K, Benesch C, Kelly A, Brehaut S, Kansara A, Schwamm L, Romano J. Functional status at 30 and 90 days after mild ischaemic stroke. Stroke And Vascular Neurology 2022, 7: 375-380. PMID: 35474180, PMCID: PMC9614160, DOI: 10.1136/svn-2021-001333.Peer-Reviewed Original ResearchModified Rankin ScaleMild ischemic strokeIschemic strokeMRS 0Stroke severityStudy populationDisability statusGreater stroke severityIschemic stroke participantsAlteplase treatmentClinical characteristicsHealth StrokeHospital arrivalRankin ScaleStroke StudyMild strokeFunctional statusMedical recordsFunctional improvementStroke participantsMultivariable modelFunctional declineLong-term recoveryIdentifies predictorsStudy participants
2019
The Mild and Rapidly Improving Stroke Study (MaRISS): Rationale and design
Romano J, Gardener H, Campo-Bustillo I, Khan Y, Riley N, Tai S, Sacco R, Khatri P, Smith E, Schwamm L. The Mild and Rapidly Improving Stroke Study (MaRISS): Rationale and design. International Journal Of Stroke 2019, 14: 983-986. PMID: 31496438, DOI: 10.1177/1747493019873595.Peer-Reviewed Original ResearchConceptsStroke symptomsStroke Impact Scale-16Actual treatment ratesMild ischemic strokePrimary safety outcomeSymptomatic hemorrhagic transformationProportion of patientsThird of patientsProspective observational studyEffect of alteplaseAcute stroke trialsLong-term outcomesPredictors of outcomeAlteplase treatmentHemorrhagic transformationIschemic strokeRankin ScaleSecondary outcomesBarthel IndexPrimary outcomeResidual disabilityStroke presentationRetrospective studyStroke StudyStroke trials